FRX Forest Road Acquisition Corp

Scott + Scott, LLC Client/Shareholder Filed Securities Lawsuit Against Forest Laboratories, Inc. - Lead Papers to be Filed on Tuesday Law Firm that Lead ImClone Litigation to Settlement Also Represents Shareholders In Case Against GlaxoSmithKline COLCHESTER, Conn., May 5 /PRNewswire/ -- Scott + Scott, LLC filed a class action securities fraud case on behalf of shareholders in the United States District Court for the Southern District of New York on behalf of a class (the "Class") consisting of all persons or entities who purchased or otherwise acquired securities of Forest Laboratories, Inc. ("Forest Labs" or the "Company") (NYSE:FRX) between August 15, 2002 and September 1, 2004, inclusive (the "Class Period"). The complaint charges Forest Labs and certain of its officers and directors with violations of the Securities Exchange Act of 1934. Forest Labs develops, manufactures and sells prescription drug products, as well as non-prescription pharmaceutical products. According to the complaint, during the Class Period, defendants caused Forest Labs' stock price to be overstated by concealing deficiencies with its Celexa/Lexapro drugs in treating adolescent depression. When Forest Labs ultimately disclosed an agreement with the New York State Attorney General to make available summaries of previously undisclosed studies on the drugs to the public, the price of Forest Labs stock dropped to as low as $36 per share. Forest Laboratories Inc. on Thursday said a Delaware federal court had delayed by seven months the start of a trial in which it will attempt to block generic forms of its Lexapro anti-depressant. Forest and its partner, Danish drugmaker H. Lundbeck A/S, are battling generic drugmaker Ivax Corp. and Australian drugmaker Alphapharm Pty. Ltd. The new trial date will be Dec. 5, instead of the earlier slated date of May 9, Forest said. To learn more about this case, you can call Neil Rothstein directly at 619/251-0887 or at . According to its website, Forest Laboratories, Inc. and its subsidiaries, develop, manufacture and sell ethical drug products, which require a physician's prescription, as well as non-prescription pharmaceutical products sold over-the-counter (OTC). The Company's products in United States consist of branded-ethical drug specialties marketed directly or detailed to physicians by the Company's Forest Pharmaceuticals, Forest Therapeutics, Forest Healthcare, Forest Ethicare and Forest Specialty Sales forces. It promotes in the United States those of its branded products, which has potential for growth and concentrates on group of physicians, who are high- prescribers of its products, such as Namenda, Forest's N-Methyl-D-Aspartate (NMDA) antagonist for the treatment of moderate to severe Alzheimer's disease; Lexapro, selective serotonin reuptake inhibitor (SSRI) for the treatment of major depression, and Benicar, an angiotensin receptor blocker for the treatment of hypertension, which Forest co-promotes with Sankyo. PROCEDURE: A plaintiff has until May 10, 2005 to move for appointment as lead plaintiff. During that time, a plaintiff has the opportunity to join Scott + Scott's Forest Laboratories client/shareholder list which permits those clients/shareholders greater access to information and discussion about the case and to receive the benefit of continued access to these attorneys as the case moves forward. If you would like to view a copy of this complaint and fill out the necessary paperwork, please contact attorney Neil Rothstein. You can also call our Connecticut office at 800/404-7770 or in California at 800/332-2259. You can dial direct in California at 619/233-4565 or reach Mr. Rothstein at 619/251-0887. Scott + Scott, LLC has its headquarters at 108 Norwich Avenue, Colchester, CT 06415; phone: 860/537-3818; fax: 860/537-4432. Scott + Scott, LLC has litigated or is the process of litigating and working on many pharmaceutical cases including: Rhodia, Cell Therapeutics, Merck, Pfizer, ImClone, GlaxoSmithKline and more. You can visit our website, under reconstruction, to learn more about the firm: http://www.scott-scott.com/ Scott + Scott, LLC is a firm that devotes most of its practice to securities, antitrust and employment benefits litigation. The firm is nationally recognized with offices in Colchester, Connecticut; San Diego, California; and Chagrin Falls, Ohio. For more information about the lawsuit or this press release, please e-mail . You can dial direct in California at 619-233-4565 or toll-free as stated above. Scott + Scott dedicates itself to client communication and satisfaction. It represents individuals, foundations, corporations and others nationwide in securities, antitrust and employee litigation. Take the time to find out more about the firm, its practice and other cases. If you wish to discuss this action with an attorney or have any questions concerning this notice, your rights or any matter within our expertise, please contact attorney Neil Rothstein as stated above or by cell: 619/251-0887. Scott + Scott, LLC is located at 108 Norwich Avenue, Colchester, CT 06415; phone: 860/537-3818; fax: 860/537-4432. This release is issued in accordance with the applicable U.S. Federal Law. DATASOURCE: Scott + Scott, LLC CONTACT: Neil Rothstein of Scott + Scott, LLC, +1-619-251-0887, Web Site: http://www.scott-scott.comc/

Copyright